The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.
Last month, Merck KGaA’s BTK inhibitor evobrutinib was put on partial clinical hold by the US Food and Drug Administration (FDA) following two reports of drug-induced liver injury.
Merck KGaA has said that the US Food and Drug Administration (FDA) has placed a partial clinical hold on new patients receiving its multiple sclerosis (MS) drug candidate evobrutinib. ... Merck is working closely with the FDA to establish the best path
Merck KGaA then teamed up with the company just over a year later in June 2022. ... identifying novel molecular glue degraders with Merck’s world class research and development capabilities.
Merck KGaA and Aqilion AB have entered into an exclusive licence and strategic research partnership to advance small molecule inhibitors of the TAK1 protein, thought to play a central role in ... Aqilion will be responsible for the design and synthesis
The collaboration will see Mersana develop novel ADC product candidates for up to two targets, utilising its platform to combine Merck KGaA's proprietary antibodies. ... Pre-clinical activities will be split between the two companies, with Merck KGaA
No results were found